Senseonics Announces New CFO

GERMANTOWN, MD--(Marketwired - January 09, 2015) -

Senseonics, Inc., a privately held medical device company focused on the development and commercialization of the first fully implantable, long-term continuous glucose monitoring (CGM) system, today announced the appointment of R. Don Elsey as the company’s new Chief Financial Officer.

Prior to joining Senseonics, Don served from May 2014 to February 2015 as the CFO of Regado Biosciences, a publicly held biopharmaceutical company who develops novel, first-in-class, actively controllable antithrombotic drug systems for cardiovascular indications. From December 2013 to March 2014, he was the CFO of LifeCell, Inc., a privately held regenerative medicine company. From June 2005 to December 2012, he served as Senior VP and CFO at Emergent BioSolutions, Inc., a publicly held biopharmaceutical company. Don served as the Director of Finance and Administration at IGEN International, Inc., a publicly held biotechnology company, and its successor BioVeris Corporation, from April 2000 to June 2005. He also served as Director of Finance at Applera and in several finance positions at International Business Machines, Inc. Don serves on the board of directors of RegeneRx Biopharmaceuticals, a publicly traded biopharmaceuticals company, as well as on the board of the Cancer Support Community. He received an M.B.A. in Finance and a B.A. in Economics from Michigan State University. Don is a certified management accountant.

Tim Goodnow, CEO and President, said, “We’re excited to have Don join us as he brings deep and relevant experience to our finance team, including a proven track record of financial planning and execution. In addition, Don will play a significant role in our international and domestic concerns as we pursue our long-term strategic objectives.”

About Senseonics
Senseonics, Incorporated is developing the first fully implantable continuous glucose sensor designed for highly accurate, long-term wear. The Senseonics Continuous Glucose Monitoring System includes a miniaturized sensor, smart transmitter and mobile medical application. Based on proprietary breakthrough fluorescence sensing technology, the sensor is designed to be inserted into the subcutaneous space of the upper arm and communicate with the smart transmitter to wirelessly transmit glucose levels to a smartphone. After insertion, the sensor functions automatically and continuously. The system is intended to enable people with diabetes to confidently live their lives with ease. For more information on Senseonics, please visit us at http://www.senseonics.com.